Clinical Trials
KRAS G12C Inhibitor Adagrasib (MRTX849)
Sponsored by Mirati
Study 849-001:
Phase 1/2 study of MRTX849 in patients with cancer having a KRASG12C mutation (KRYSTAL-1)
Study 849-002:
Phase 1/2 study of MRTX849 in combination with TNO-155 in patients with cancer having a KRASG12C mutation (KRYSTAL-2)
Study 849-007:
Phase 2 study of MRTX849 in combination with pembrolizumab in NSCLC patients having a KRASG12C mutation (KRYSTAL-7)
Study 849-010:
Phase 3 study of MRTX849 with cetuximab vs chemotherapy in patients with CRC with KRASG12C mutation (KRYSTAL-10)
Study 849-012:
Phase 3 study of MRTX849 vs docetaxel in patients with NSCLC with KRASG12C mutation (KRYSTAL-12)
Study 849-014:
A Phase 1/1b study of MRTX849 in combination with BI 1701963 in patients with advanced solid tumors with KRASG12C mutation (KRYSTAL-14)
Adagrasib collaborative trials are run by Zai Lab, Sanofi, Novartis, Boehringer Ingelheim, respectively.
MTA-Cooperative PRMT5 Inhibitor (MRTX1719)
Sponsored by Mirati
Study 1719-001:
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
SOS1 (MRTX0902)
Sponsored by Mirati
Study 0902-001:
Phase 1/2 Study of MRTX0902 in Solid Tumors with Mutations in the KRAS-MAPK Pathway
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can decide if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate. If you have questions about treatment of your medical condition, consult a qualified healthcare professional.
To identify clinical trials that match your diagnosis, treatment history and location, call 1-844-893-5530 or use our online Study Locator